Eri Taguchi

KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties

Kazuhide Nakamura, Eri Taguchi, Atsushi Yamamoto et al. · Cancer Research · 2006 · 204 citations · Full text

KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth

Kazuhide Nakamura, Atsushi Yamamoto, Masaru Kamishohara et al. · Molecular Cancer Therapeutics · 2004 · 66 citations · Full text

One-Step Conjugation Method for Site-Specific Antibody–Drug Conjugates through Reactive Cysteine-Engineered Antibodies

Daisuke Shinmi, Eri Taguchi, Junko Iwano et al. · Bioconjugate Chemistry · 2016 · 61 citations

Immunocytochemical Technique, Immunology, Immunotherapeutics +22

In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors

Yumi Sasayama, Maki Hasegawa, Eri Taguchi et al. · Journal of Controlled Release · 2019 · 40 citations

Nanoparticles, Nanomedicine, Efficient Sirna Delivery +11

Anti‐tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model

Eri Taguchi, Kazuhide Nakamura, Toru Miura et al. · Cancer Science · 2008 · 34 citations · Full text